These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 27510503)

  • 1. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
    Garnock-Jones KP
    Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
    Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Vallejos W; Liang LW; Noga SJ; Rapoport BL
    Ann Oncol; 2016 Jan; 27(1):172-8. PubMed ID: 26449391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types.
    Aapro MS; Schmoll HJ; Jahn F; Carides AD; Webb RT
    Cancer Treat Rev; 2013 Feb; 39(1):113-7. PubMed ID: 23062719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
    Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
    BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
    Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
    BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
    Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Pong A; Noga SJ; Rapoport BL
    Support Care Cancer; 2018 Nov; 26(11):3773-3780. PubMed ID: 29808377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting.
    Van Belle SJ; Cocquyt V
    Expert Opin Pharmacother; 2008 Dec; 9(18):3261-70. PubMed ID: 19040346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
    Rapoport BL; Jordan K; Boice JA; Taylor A; Brown C; Hardwick JS; Carides A; Webb T; Schmoll HJ
    Support Care Cancer; 2010 Apr; 18(4):423-31. PubMed ID: 19568773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study.
    Yang LQ; Sun XC; Qin SK; Cheng Y; Shi JH; Chen ZD; Wang QM; Zhang HL; Hu B; Liu B; Zhang QY; Wu Q; Wang D; Shu YQ; Dong J; Han BH; Wang KM; Dang CX; Li JL; Wang HB; Li BL; Lu JG; Zhang ZH; Chen YX
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28393417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aprepitant: a review of its use in the prevention of nausea and vomiting.
    Curran MP; Robinson DM
    Drugs; 2009; 69(13):1853-78. PubMed ID: 19719336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
    Hesketh PJ; Warr DG; Street JC; Carides AD
    Support Care Cancer; 2011 Sep; 19(9):1297-302. PubMed ID: 20623144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
    Aapro M; Carides A; Rapoport BL; Schmoll HJ; Zhang L; Warr D
    Oncologist; 2015 Apr; 20(4):450-8. PubMed ID: 25795636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.
    Pritchett W; Kinsley K
    Clin J Oncol Nurs; 2016 Oct; 20(5):555-6. PubMed ID: 27668376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
    Molassiotis A; Nguyen AM; Rittenberg CN; Makalinao A; Carides A
    Future Oncol; 2013 Oct; 9(10):1443-50. PubMed ID: 23987791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
    Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic evaluation of fosaprepitant dimeglumine.
    Colon-Gonzalez F; Kraft WK
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1277-86. PubMed ID: 20795794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.